Navigation Links
Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
Date:6/19/2013

zing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development with partners when and where appropriate.

Presently, Pharmacyclics has two product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in thi
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
2. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
3. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
4. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
5. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
8. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
10. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
11. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... BOSTON , December 15, 2014 ... discovery and development company, is pleased to announce the ... United States relating to its GPCR-focused drug ... US significantly strengthens the global patent estate covering Heptares, ... The suite of patents recently granted by the ...
(Date:12/13/2014)... , Dec. 12, 2014  Radiologists can transmit ... images, to their referring physicians, electronic health records ... carefully selected technology.  That was ... Systems Corporation (ADS) at the recent Radiology Society ... transmitting of radiology reports in this manner also ...
(Date:12/13/2014)... and INDIANAPOLIS , Dec. 12, ... and Chip Ganassi Racing Teams (CGRT), today announced a multi-year ... the primary sponsor of the No. 83 Novo Nordisk Chip ... the Verizon IndyCar Series. Kimball, 29, from ... only licensed driver with diabetes in the history of INDYCAR ...
Breaking Medicine Technology:Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7
... August 27 , - Oralair(R) Grasses 300IR Highly ... Allergen Challenge Chamber, Stallergenes S.A. announces the highly ... Challenge Chamber (ACC)., The study on Oralair(R) Grasses ... different treatment durations: 1 week, 1 month,2 and 4 ...
... INDIANAPOLIS, Aug. 26 Semafore Pharmaceuticals Inc.,announced data ... in Cancer in Washington, D.C., showing additional antiangiogenic,activity ... both VEGF and Bv8 signaling., PI3K is ... /mTOR pathway that,has been shown to play a ...
Cached Medicine Technology:Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... ... medical device industry expands its precision micro-machining facility, increases work force to three shifts ... ... Medical,s San Diego facility has completed a multi-million dollar expansion in order to integrate ...
... NEW YORK, Oct. 20 Philips is delivering on their ... the launch of Philips DirectLife, a new customized, interactive fitness ... eager to adopt a more active lifestyle. The DirectLife program ... the more than 60 percent of the global population who ...
... announced a donation of $211,306 from Eagle Golf, the Dallas-based ... Club at Castle Hills in Lewisville, Texas. From Sept. 1-Oct. ... a Swing at Cancer" to raise awareness and funds for the ... Eagle Golf and its patrons for supporting our work on behalf ...
... children are already anticipating Halloween "trick or treating," some parents ... door-to-door to receive free candy. , Parents of ... when their child is the recipient of food outside the ... allergy can stay safe without having to miss out on ...
... lie when it comes to showing signs of aging. Yet ... Studies have demonstrated that volume loss of soft tissue and ... loss of volume in the face over time can cause deep ... With the recent FDA approval of Scrulptra® Aesthetic, physicians now have ...
... 1. For Patients with Erectile Dysfunction, Treatment with ... and Erectile Function , ACP issues clinical practice ... inhibitor drugs used to treat patients with ED, ... the treatment of erectile dysfunction (ED). ACP strongly ...
Cached Medicine News:Health News:Johnson Matthey Expands San Diego Facility 2Health News:Philips Launches DirectLife, a New Personal Fitness Program to Help People Lead Healthier Lives 2Health News:Philips Launches DirectLife, a New Personal Fitness Program to Help People Lead Healthier Lives 3Health News:Philips Launches DirectLife, a New Personal Fitness Program to Help People Lead Healthier Lives 4Health News:LIVESTRONG(R) Receives $211,306 Donation from Eagle Golf 2Health News:Halloween Doesn't Have to Be Scary for Kids With Food Allergies 2Health News:Pumping Up the Volume in the Face to Reduce Signs of Aging 2Health News:Pumping Up the Volume in the Face to Reduce Signs of Aging 3Health News:Embargoed news from Annals of Internal Medicine 2Health News:Embargoed news from Annals of Internal Medicine 3
... the art in inverted microscopy from Zeiss. ... range of ICS objectives, with innovative condensers ... an unusual scope of sophisticated documentation and ... designed. And Axiovert 200 M, fully motorized, ...
... TS100 is an innovative and efficient ... tool complements any research facility. Improved ... Nikon offers the TS100 binocular and ... model comes with a photo port ...
... direct digital output. Three-chip color camera for ... array of high-quality color video cameras give ... you need for an efficient viewing experience. ... image of your specimen that can be ...
... Tech GT-Capture digital camera photomicrographic system can ... such as Olympus, Leica, Nikon, and Zeiss, ... transferring images over the Internet easy and ... a performance-proven Nikkor lens. The system records ...
Medicine Products: